Nadia M Randazzo1,2, Morag E Shanks3, Penny Clouston3, Robert E MacLaren1,2. 1. a NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust , Oxford , United Kingdom. 2. b Oxford Eye Hospital, University of Oxford NHS Trust, John Radcliffe Hospital , Oxford , United Kingdom. 3. c Oxford Medical Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust Churchill Hospital , Oxford , United Kingdom.
Abstract
Purpose: We report two new CAPN5 mutations associated with a phenotype of Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. Methods: We performed next generation sequencing in two patients with ADNIV phenotype; the variants identified were explored further. Results: Patient 1 was heterozygous for CAPN5 c.799G>A, p.(Gly267Ser). Patient 2 was heterozygous for CAPN5 c.1126G>A, p.(Gly376Ser). Both amino acids are highly conserved across species. Patient 1 had a severe phenotype and his mutation lies within the protein's catalytic domain. Patient 2 had a mild phenotype and her mutation is the first ADNIV-causing mutation to be described in the regulatory domain of Calpain-5. Conclusions: Our findings potentially add two new ADNIV-causing CAPN5 mutations to the three previously described. We recommend CAPN5 genetic testing in all patients with a possible ADNIV phenotype, to develop our understanding of Calpain-5; a protein which could potentially provide therapeutically accessible targets for the treatment of many leading causes of blindness.
Purpose: We report two new CAPN5 mutations associated with a phenotype of Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. Methods: We performed next generation sequencing in two patients with ADNIV phenotype; the variants identified were explored further. Results: Patient 1 was heterozygous for CAPN5 c.799G>A, p.(Gly267Ser). Patient 2 was heterozygous for CAPN5 c.1126G>A, p.(Gly376Ser). Both amino acids are highly conserved across species. Patient 1 had a severe phenotype and his mutation lies within the protein's catalytic domain. Patient 2 had a mild phenotype and her mutation is the first ADNIV-causing mutation to be described in the regulatory domain of Calpain-5. Conclusions: Our findings potentially add two new ADNIV-causing CAPN5 mutations to the three previously described. We recommend CAPN5 genetic testing in all patients with a possible ADNIV phenotype, to develop our understanding of Calpain-5; a protein which could potentially provide therapeutically accessible targets for the treatment of many leading causes of blindness.
Authors: R Kirschner; T Rosenberg; R Schultz-Heienbrok; S Lenzner; S Feil; R Roepman; F P Cremers; H H Ropers; W Berger Journal: Hum Mol Genet Date: 1999-08 Impact factor: 6.150
Authors: Joel David; Aleksandr Melamud; Leo Kesner; Steven Roth; Pearl S Rosenbaum; Frank C Barone; Sussana Popp; Getaw Worku Hassen; Alfred Stracher; Daniel M Rosenbaum Journal: Neuroreport Date: 2011-09-14 Impact factor: 1.837
Authors: Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio Journal: Mol Ther Date: 2009-12-01 Impact factor: 11.454
Authors: Katherine J Wert; Susanne F Koch; Gabriel Velez; Chun-Wei Hsu; MaryAnn Mahajan; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan Journal: Hum Mutat Date: 2019-08-26 Impact factor: 4.878
Authors: Peter Charbel Issa; Peggy Reuter; Laura Kühlewein; Johannes Birtel; Martin Gliem; Anke Tropitzsch; Katherine L Whitcroft; Hanno J Bolz; Kenji Ishihara; Robert E MacLaren; Susan M Downes; Akio Oishi; Eberhart Zrenner; Susanne Kohl; Thomas Hummel Journal: JAMA Ophthalmol Date: 2018-07-01 Impact factor: 7.389
Authors: Mital Shah; Suzanne Broadgate; Morag Shanks; Penny Clouston; Jing Yu; Robert E MacLaren; Andrea H Németh; Stephanie Halford; Susan M Downes Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Peter H Tang; Teja Chemudupati; Katherine J Wert; James C Folk; MaryAnn Mahajan; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan Journal: Am J Ophthalmol Case Rep Date: 2020-02-24
Authors: Gabriel Velez; Alexander G Bassuk; Kellie A Schaefer; Brian Brooks; Lokesh Gakhar; MaryAnn Mahajan; Philip Kahn; Stephen H Tsang; Polly J Ferguson; Vinit B Mahajan Journal: Cold Spring Harb Mol Case Stud Date: 2018-06-01
Authors: Gabriel Velez; Young Joo Sun; Saif Khan; Jing Yang; Jonathan Herrmann; Teja Chemudupati; Robert E MacLaren; Lokesh Gakhar; Soichi Wakatsuki; Alexander G Bassuk; Vinit B Mahajan Journal: Cell Rep Date: 2020-01-21 Impact factor: 9.423